BYSI.US BeyondSpring Inc

Healthcare Biotechnology USA Stocks
0.6012 USD
Close of Nov 14, 2026
0.4220 2.44
Market cap
USD 24.7M
P/E
-
P/B
5.38x
ROE
-39.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BYSI.US undervalued?

Graham number

The Graham number of BeyondSpring Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BeyondSpring Inc fundamental analysis

No fundamental analysis for BeyondSpring Inc yet.

BeyondSpring Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer…

Full company profile